USANA Health Sciences reports Q3 2026 loss and lowers full‑year outlook
+1 new source since this summary was written
USANA Health Sciences posted third‑quarter 2026 net sales of about $206 million, a net loss of $5.6 million and diluted EPS of $(0.30). Adjusted earnings were $(0.11) per share and adjusted EBITDA was $12.1 million. The company revised its fiscal 2026 guidance, now expecting net sales of $900 million and adjusted EBITDA of $77 million, and lowered its full‑year EPS outlook to $0.55 per share.
Why it matters
The lowered revenue and EPS guidance signals weaker near‑term growth, which may pressure USNA’s share price (the company noted the guidance change in its filing and the earnings summary). Investors will reassess valuation and cash‑flow expectations based on the updated outlook.
Key facts
- 1Net sales were $206 million for Q3 2026 versus $214 million a year earlier. sec.gov
- 2Net loss was $(5.6) million for the quarter, compared with $(6.5) million a year earlier. sec.gov
- 3Diluted EPS was $(0.30) for Q3 2026, versus $(0.36) a year earlier. sec.gov
- 4Adjusted diluted EPS was $(0.11) for Q3 2026, versus $(0.15) a year earlier. sec.gov
- 5Adjusted EBITDA was $12.1 million for Q3 2026, versus $13.8 million a year earlier. sec.gov
- 6Core Nutritional active customers numbered 356,000, down from 388,000 a year earlier. sec.gov
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.